Respiratory infection test kit RP2.1- EZ

SARS-COV-2coronavirusinfluenza A

Now authorized by the FDA through an Emergency Use Authorization, the BioFire RP2.1-EZ Panel (EUA)* uses a syndromic approach to quickly identify SARS-CoV-2, along with 18 additional viral and bacterial pathogens in patients suspected of SARS-CoV-2. This PCR test provides results in about 45 minutes. As a healthcare provider, this means your patients can receive the right treatment the first time, leading to shorter appointment times and improved antimicrobial stewardship.1 The BioFire RP2.1-EZ Panel (EUA)* is designed to run on the BioFire® FilmArray® 2.0 EZ Configuration System, which is intended to be used in near-patient settings. Onsite Respiratory Diagnostics. Traditionally, clinical care of respiratory tract infections is designed around syndromic disease management and centralized laboratory testing.3 Now laboratory testing is shifting to decentralized, near-patient settings, creating a simplified process with faster results.4 With the shift toward value-based care, syndromic testing from BioFire can help you do what is best for the patient while reducing untimely and expensive send-out tests. The BioFire RP2.1-EZ Panel (EUA) may help improve clinician confidence in diagnosis, aid in antimicrobial stewardship, improve patient management, enhance diagnostic yield, and reduce appointment duration. Leave No Stone Unturned With Syndromic Respiratory Testing. Because a large number of pathogens cause respiratory infections, tests that only identify SARS-CoV-2 or influenza run the risk of missing the real culprit.